Ernexa Therapeutics Finalizes Reverse Stock Split Plan to Avoid Nasdaq Delisting

summarizeSummary

Ernexa Therapeutics Inc. has filed a definitive information statement for a reverse stock split, with a ratio between 1-for-10 and 1-for-25, to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events · Corporate Governance and Compliance · ERNA

• Shareholders Approve Reverse Stock Split

  On March 27, 2026, shareholders representing approximately 53.34% of voting power approved a reverse stock split, granting the Board discretionary authority to set a ratio between 1-for-10 and 1-for-25.

• Aims to Regain Nasdaq Compliance

  The primary purpose of the reverse split is to increase the per-share trading price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting, following the preliminary announcement on April 1, 2026.

• Effective Date Imminent

  The reverse split will become effective no earlier than 20 calendar days after this definitive information statement is mailed, which is on or about April 13, 2026.

• Authorized Shares Unchanged, Potential for Future Dilution

  The total number of authorized common shares will remain at 150,000,000, meaning the reverse split will significantly increase the proportion of unissued shares, providing flexibility for future equity financings but also potential for substantial dilution.

auto_awesomeAnalysis · ERNA · Life Sciences

This definitive information statement confirms the company's plan to execute a reverse stock split, a critical measure to address its non-compliance with Nasdaq's minimum bid price requirement. Following the preliminary filing on April 1, 2026, this DEF 14C indicates that majority shareholders have already approved the action, granting the Board discretion to implement a ratio between 1-for-10 and 1-for-25. While necessary to prevent delisting, a reverse split often signals underlying financial distress and does not guarantee sustained price improvement or long-term compliance. The unchanged number of authorized shares (150,000,000) post-split will significantly increase the proportion of unissued shares, providing substantial headroom for future dilutive equity financings, which is a common concern for micro-cap companies like Ernexa Therapeutics, especially given its previously disclosed going concern doubts.